 The purpose of the study is to investigate drug costs and adverse effects of low-dose neostigmine 0.025 mgkg plus low-dose sugammadex 1 mgkg for reversal of rocuronium-induced neuromuscular block, and compare efficacy of antagonism and costs of this combination therapy with the current standard therapies: full-dose sugammadex 2 mgkg and full-dose neostigmine 0.05 mgkg plus atropine. 